Type:10 Tablets
Generic Name:Trifluoperazine
Manufacturer:Healthcare Pharmaceuticals Ltd.
Price:৳20.00
Anxiety, Psychoses, Nausea and vomiting, Schizophrenia
Should be taken with food.
Oral Psychoses, Schizophrenia Adult: Outpatient 1-2 mg PO q12hr Inpatient Initial: 2-5 mg PO q12hr Maintenance Dose: 15-20 mg/day Not to exceed 40mg/day Short-term management of anxiety Adult: 1-2 mg bid. Max: 6 mg daily. Max duration: 12 wk. Elderly: Initiate at lower dose and increase gradually.
Schizophrenia/Psychosis Inpatient <6 years: Safety and efficacy not established 6-12 years old: 1 mg PO qDay or q12hr; not to exceed 15 mg/day 12 years old: 2-5 mg PO q12hr
Preexisting CNS depression and coma; bone marrow depression, blood dyscrasias, liver disease, hypersensitivity to phenothiazines, prolactin dependent tumours. Pregnancy (1st trimester), lactation.
Trifluoperazine inhibits dopamine D2 receptors in the brain. It has weak anticholinergic and sedative effects but strong extrapyramidal and antiemetic effects. It controls severely disturbed, agitated or violent behaviour but may also be used for nonpsychotic anxiety.
Cardiovascular disease, epilepsy, angle-closure glaucoma, exposure to extreme temperatures, elderly, parkinson's disease, myasthenia gravis, benign prostatic hyperplasia, DM, renal amd hepatic impairment. Discontinue trifluoperazine at least 48 hr before myelography and do not resume for at least 24 hr after procedure. Do not use trifluoperazine in control of nausea and vomiting occurring either prior to myelography or postprocedure with metrizamide. Pregnancy.
EPS (60%; muscle stiffness, dystonia, parkinsonism, tardive dyskinesia, akathisia), Drowsiness, dry mouth, blurred vision, dizziness, sedation, antimuscarinic affects, postural hypotension, akathisia, muscle weakness, anorexia, insomnia, rash, amenorrhoea, fatigue, increased prolactin levels. Potentially Fatal: Neuroleptic malignant syndrome, blood dyscrasias.
Increased CNS depression with CNS depressants such as opiates or other analgesics, barbiturates or other sedatives, general anaesthetics, or alcohol. Increased risk of side effects with drugs with antimuscarinic properties e.g. TCA, antiparkinsonian drugs. Antagonised effects of dopaminergic drugs such as levodopa. Increased risk of hypotension with antihypertensives, trazodone. Reverses antihypertensive effect of guanethidine. Increased risk of severe extrapyramidal side-effects or severe neurotoxicity with lithium. Possible decrease in absorption with antacids.
